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Donor site morbidity, poor graft site integration, and incorrect mechanical performance are all common problems associated with
autografts for anterior cruciate ligament (ACL) reconstructions. A tissue-engineered (TE) ligament has the potential to overcome
these problems. We produced an online questionnaire relating to tissue engineering of the ACL to obtain input from practising
clinicians who currently manage these injuries. 300 British orthopaedic surgeons specialising in knee surgery and soft tissue injury
were invited to participate. 86% of surgeons would consider usinga TE ACLif it were an option, provided that it showed biological
and mechanical success, if it signiﬁcantly improved the patient satisfaction (63%) or shortened surgical time (62%). 76% felt that
using a TE ACL would be more appropriate than a patellar tendon, hamstring, or quadriceps autograft. Overall, most surgeons
would be prepared to use a TE ACL if it were an improvement over the current techniques.
1.Introduction
Some of the most frequently ruptured ligaments occur in the
knee joint, often through sporting activities such as skiing,
football, and basketball. Ninety percent of knee ligament
injuries involve the anterior cruciate ligament (ACL) and
medial collateral ligament (MCL) [1]. The MCL can self-
heal, but the ACL is not able to do so from a combination of
poor vascularisation and its intra-articular location. There-
fore, alternative methods, including regenerative medicine,
have focused heavily upon the ACL with the aim of produc-
ing a fully functional tissue in vitro.
The current gold standard procedure to reconstruct a
torn ACL is surgical autografting. This involves using part of
the patients own patellar, hamstring, or quadriceps tendon
to replace the torn ACL [2]. However, this causes donor
site morbidity [3–6] and is associated with pain and a
recovery period for this region [5, 6]. Generally, 75–90% of
patients have good or excellent long-term success rates from
the current reconstruction techniques regarding functional
stabilityandsymptomaticreliefuponreturntonormalactiv-
ities, but many patients experience unsatisfactory results,
which could be attributed to graft failure [7]. Some of these
patients continue to endure pain, suﬀer from loss of motion
secondary to the procedure, and their instability is not cor-
rected [7]. Others suﬀer from degenerative joint disease such
as osteoarthritis or experience reinjury [6]. Alternatively,
allografts can be used; in this instance, the donor tendon is
taken from a cadaver, but the disadvantages associated with
thisincludescarcityofsuitabletissue,theriskoftherecipient
contracting a disease from the donor, or tissue rejection [8,
9].Prostheticreplacements(syntheticgrafts)havepreviously
been used, but they are inadequate due to wear and degen-
eration [10]. Surgical reconstruction techniques have limita-
tionsanddonotalwaysprovidecompletelysatisfactorylong-
term results in a high proportion of patients, consequently
aﬀecting their quality of life [7, 11]. Because of this dilemma,
regenerative medicine could be an option, whereby in vitro
tissue engineering of ligaments could oﬀer a solution to
the problems associated with the current surgical methods
[4, 6]. Tissue-engineered ligaments could provide better
performance in the long run by improved biocompatibility,
better integration into host tissue, and the ability to remodel
their own extracellular matrix [12].2 Stem Cells International
Tissue engineering is a method which combines knowl-
edge from material science, engineering, molecular biology,
and medicine [12] .T h eb a s i cp r o c e d u r en o r m a l l yi n v o l v e s
using scaﬀo l d st oa c ta ss t r u c t u r a ls u p p o r t sf o rc e l lg r o w t h
and maturation in vitro, where a chemical or mechanical
stimulus may also be applied to promote the formation of
a functional tissue. This concept was originally developed to
repair skin, cartilage, and bone, but is now being considered
as a possible option to produce a functional ACL.
It is important to have input from some of the end users,
namely,theorthopaedicsurgeons,ondevelopingtissueengi-
neering strategies so that scientists working in this area can
determine whether their research is heading in the correct
direction. We wanted to ascertain whether the orthopaedic
surgeons that routinely carry out ACL reconstruction would
choose to use a-tissue engineered ACL for implantation if it
were an option and to elucidate any reservations that they
may have regarding this emerging technology. Therefore, we
developed an online questionnaire to investigate the current
clinical opinion on using tissue- engineered ACLs to treat
their future patients.
2.MaterialsandMethods
An online questionnaire was designed to ascertain how sat-
isﬁed knee surgeons were with the current autografting
methods for ACL reconstructions and to gain their opinions
towards using a tissue-engineered ACL for implantation as
an alternative method to the current autografting procedure.
We also wanted to determine whether the surgeons felt
it would be advantageous to surgeon, patient, and the
National Health Service (NHS) to use a tissue-engineered
ACL. The following questions and responses were included
as described in Table 1.
M a n yo ft h eq u e s t i o n sa b o v er e q u i r e d“ Y e s ,N oo rD on o t
know”answers,whileotherswerecategorisedorrequiredthe
input of values. The questionnaire was peer reviewed and
subsequently approved by the local research ethics commit-
tee (Project no. 09/H1204/64, approved 15/10/09). Between
July and October 2010, 300 orthopaedic surgeons specialis-
ing in knee surgery and soft tissue injury in the UK were
contacted by e-mail and invited to participate. From this e-
mailed input request, 79 surgeons responded.
The sample of surgeons contacted for inclusion in this
study were those who were members of the British Ortho-
paedic Association (BOA), who also belonged to one of two
specialist societies, the British Association of Surgery of the
Knee (BASK) and the British Orthopaedic Sports Trauma
Association (BOSTA). The e-mail addresses were obtained
from the BOA handbook of 2006, where the invitation and
link to the survey was sent to 300 surgeons. Reminders
(aimed at nonresponders) were sent at 8 days, 42 days, and
again at 69 days after the ﬁrst invitation to ask for their
feedback. The results remained anonymous and were anal-
ysed using Microsoft Excel.
3. Results
The overall response rate in total was 26% (79/300): we did
not receive an answer from 221 surgeons. Of those who did
respond, 10% (8/79) did not perform ACL reconstruction
and,therefore, could not provide feedback. Most of the sur-
geons who completed the survey had been an orthopaedic
consultant for more than 10 years (62%, 44/71), with 15%
(11/71) of the respondents having been a consultant for less
than 5 years. Sixteen of 71 (23%) respondents had been
an orthopaedic consultant for 5 to 10 years. From the 71
surgeons, 69% (49/71) had over 10 years of experience
performing ACL reconstructions, with 23% (16/71) having
5–10 years of experience, and 8% (6/71) having less than 5
years of experience.
The average number of ACL reconstructive surgeries that
wereperformedbytherespondentseverymonthvariedfrom
1to15.Themajorityofrespondents(77%,55/71)performed
between 2 and 8 ACL reconstructions a month.
Forty-eight surgeons (68%, 48/71) responded to ques-
tion 5 regarding their opinion of the current success of using
the patellar tendon as an ACL repair. More surgeons
(a total of 66/71, 93%) completed question six regarding
their opinion of the treatment success of the hamstring
tendon for ACL repair, whereas fewer surgeons (13%, 9/71)
responded to question 7 regarding their opinion on the use
of the quadriceps tendon for ACL repair. Figure 1 shows the
opinion of the respondents with regards to the success of
each of these three currently used ACL treatment methods.
The majority of surgeons (86%, 41/48) found patellar
tendonautograftstobeverysuccessful/successfulfortreating
athletes (any age) and adults of 16–40 years in age. On
average,54% (26/48) of surgeonsfelt that the patellartendon
was very successful/successful in patients with a lower typical
daily exercise regime who were 56 years or older. Surgeons
felt that the patellar tendon was either satisfactory (32%,
15/48) or very unsuccessful/unsuccessful (13%, 6/48) for
these older patients.
The hamstring tendon procedure was viewed by 88%
(58/66) of surgeons to be very successful/successful for ath-
letes (any age) and patients with “normal” activity up to the
age of 40. 73% (48/66) of surgeons felt that this procedure
was very successful/successful for patients with “normal”
activity over the age of 56. Surgeons felt that for these
patients (older than 56 years of age) the hamstring tendon
procedure was either suﬃcient (23%, 15/66) or very unsuc-
cessful/unsuccessful (3%, 2/66).
Fewer surgeons felt that the use of quadriceps tendon
was very successful/successful for young athletes (42%, 4/9)
and athletes over 26 years (66%, 6/9) in comparison to the
patellar tendon and hamstring tendon. In these cases, 25–
28% of surgeons felt that this technique was unsuccessful for
all people (all ages and activity levels).
Of 71 surgeons, 67 (94%) were familiar with the term
tissue engineering and its implications as a future therapy.
86% of the surgeons (61/71) felt that they would consider
using a tissue-engineered ACL as a treatment provided that
it had demonstrated biological and mechanical success in
vitroand in vivo. 6% (5/79) surgeons would not consider this
treatment option, and a further 8% (6/79) were unsure.
Thetimethatthesurgeonsstatedtheywouldbeprepared
to wait for a tissue-engineered ACL to be prepared varied
from 2 to 26 weeks. From the 64 who answered this question,Stem Cells International 3
Table 1: Questionnaire used online for orthopaedic consultant feedback.
Question
1 How many years have you been a consultant?
2 Do you perform anterior cruciate ligament (ACL) reconstructions?
3 Approximately how many ACL reconstructions do you perform each month?
4 How long have you been performing ACL reconstructions?
5 How successful do you rate patellar tendon ACL reconstructions? (e.g., the patient being able to return to physical activities
without experiencing another injury to the reconstructed ACL)
6 How successful do you rate hamstring ACL reconstructions? (e.g., the patient being able to return to physical activities without
experiencing another injury to the reconstructed ACL)
7 How successful do you rate quadriceps ACL reconstructions? (e.g., the patient being able to return to physical activities without
experiencing another injury to the reconstructed ACL)
8 Are you familiar with tissue engineering as future clinic therapy? (Deﬁnition of tissue engineering: To grow autologous tissue in
vitro in order to replace damaged body parts.)
9 If tissue engineering an ACL for the patient were an option (either through the NHS or privately), would you consider using a
newly developed tissue-engineered ACL? (If it had shown mechanical and biological success in vitro and in vivo)
10 If an autologous tissue were tissue-engineered in the laboratory, what time limit would you see as acceptable from the moment the
patients cells were harvested to the moment the engineered ACL was ready for implantation?
11 If you were to hypothetically use a tissue-engineered ACL, would you be concerned about the successful integration of the
engineered ACL into the bone?
12 An engineered ACL could be an exact match to the native ACL. Do you feel that this would be more appropriate for implantation
than a hamstring, quadriceps, or patellar tendon (which are only similar in tissue type to the ACL and not an exact match)?
13 Approximately how long on average does your current treatment strategy for ACL replacement take (a) regarding operation length
(b) regarding full recovery time with no pain
14 Do you think it is likely that some patients would prefer to wait to receive a tissue-engineered ACL from their own cells, rather than
receiving the current surgical ACL reconstruction using their own patellar tendon/hamstring tendon/quadriceps tendon?
15 With respect to tissue engineering
(a) Do you believe that using a tissue-engineered ligament would produce less scarring? Donor site scarring (e.g. patellar tendon,
hamstring, quadricep), implant site scarring, skin scarring as a result from donor tissue harvest?
(b) Do you believe that using a tissue-engineered ligament would take less surgical time?
(c) By how much would surgical time need to be reduced for you to consider it to be a signiﬁcant improvement?
(d) Do you believe that using a tissue-engineered ligament would give patients a shorter full recovery time?
(e) By how much would recovery time need to be reduced for you to consider it to be a signiﬁcant improvement?
(f) Do you believe that using a tissue-engineered ligament would give recovering patients reduced pain or recurring injuries?
16
Currently ACL reconstructions cost £2,061 (NHS) and £3,500–£5,000 (privately). If a tissue-engineered construct cost more than
your current procedure (for instance, up to twice the amount) but signiﬁcantly improved the patient’s satisfaction (resolution of
instability/mobility/strength), would you consider using this technique?
17 Any other personal suggestions? For example, what do you see as an advantage/disadvantage regarding using tissue-engineered
constructs? Do you see a need to improve current surgical techniques?
the majority (59/64) would wait up to 12 weeks. Of those 59
surgeons, 8% (5/59) felt that they would be prepared to wait
4 weeks, 44% (26/59) 6 weeks, 12% (7/59) 8 weeks, and 36%
(21/59) said they would wait 12 weeks for such an implant to
be ready for clinical use.
The surgical opinion of concern regarding the successful
integration of a tissue-engineered ligament into the native
bonewasasfollows:veryconcerned(25%,18/71),concerned
(42%, 30/71), slightly concerned (15%, 11/71), not particu-
larly concerned (15%, 11/71), and not at all concerned (1%,
1/71).
75% (53/71) of the participating surgeons felt that it was
more appropriate to use a tissue-engineered ACL which had
the capability to be an exact match to the native ACL than
thecurrentlyusedtendonautografts.10%(7/71)ofsurgeons
felt that it was not more appropriate, and 14% (10/71) of
surgeons did not know.
The length of time taken for the surgeons to operate
using their current tendon autograft technique varied from
approximately 60 to 90 minutes per operation. The surgeons
stated that recovery time for these currently used autograft
techniques for ACL treatment varied from 1 to 18 months,
with 10% (7/71) surgeons stating 2 months, 43% (31/71)
surgeons stating 6 months, and 13% (9/71) surgeons stating
9 months are needed for full recovery time after surgery. The
minority(34%)suggestedthatalongerperiodwasnecessary.
The surgeons felt that 60% (43/71) patients would prefer
to wait for a tissue-engineered ACL to be prepared for their
ACL repair instead of using current techniques. Another
28% (20/71) of surgeons were unsure of what the patients4 Stem Cells International
0 50 100
     Adults 
(56 years +)
      Adults 
(41–55 years)
      Adults 
(26–40 years)
   Athletes 
(26 years +)
  Young adults
(16–25 years)
  Young athletes
(16–25 years)
Opinion % of surgeons
(a) Hamstring tendon autograft success
02 0 4 0 6 0
     Adults 
(56 years +)
      Adults 
(41–55 years)
      Adults 
(26–40 years)
   Athletes 
(26 years +)
  Young adults
(16–25 years)
  Young athletes
(16–25 years)
Opinion % of surgeons
(b) Patellar tendon autograft success
Very successful
Successful
Sufficient
Unsuccessful
Very unsuccessful
02 0 4 0 60
     Adults 
(56 years +)
      Adults 
(41–55 years)
      Adults 
(26–40 years)
   Athletes 
(26 years +)
  Young adults
(16–25 years)
  Young athletes
(16–25 years)
Opinion % of surgeons
(c) Quadricep tendon autograft success
Figure 1: Graphs demonstrating current surgical opinion on the success rate of the use of (a) hamstring tendon, (b) patellar tendon, and
(c) quadriceps tendon for the repair of anterior cruciate ligament injuries.Stem Cells International 5
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Figure 2: Graph to demonstrate the % of surgeons who believe that using a tissue-engineered ligament would produce less scarring in
relation to location in the body.
response would be, and 11% (8/71) felt that the patient
would probably not prefer to wait for a tissue-engineered
ligament to be produced for them.
Figure 2 shows the opinions of the surgeons regarding
whether scarring will or will not be reduced as a result of
using tissue-engineering as a new therapy for ACL recon-
struction. 77% (55/71) of the surgeons felt there would be
less scarring at the donor site as a result of using tissue-
engineered implants. 62% (44/71) of surgeons believed that
using a tissue-engineered ACL would reduce operative time,
24% (17/71) felt that time would not be reduced in surgery,
and 14% (10/71) stated that they were unsure if surgery
time would be reduced. The surgeons felt that anywhere
b e t w e e n5a n d3 0m i n u t e sr e d u c t i o no ns u r g e r yt i m ew o u l d
be of signiﬁcant improvement to them, with 39% (28/71)
of surgeons stating that 10 to 15 minutes would make a
diﬀerence to them and 21% (15/71) stating that 20 minutes
would be beneﬁcial.
When surgeons were asked whether they believed that
using a tissue-engineered ligament would give patients a
shorter full recovery time, 23% (16/71) said yes, 47% said
no (33/71), and 30% (21/71) were unsure. When questioned
further to discover how much the patient recovery time
needed to be reduced for them to consider it to be a
signiﬁcant improvement, the surgeons replies (from a total
of 47 who responded to this question) varied between 4 and
26weeks.Themajority(45/47)indicatedthereneededtobea
reductionofupto12weeks.33%(15/45)ofsurgeonsfeltthat
a 4-week reduction in recovery time would be signiﬁcant,
38% (17/45) felt 6 weeks would, and 29% (13/45) felt that
12 weeks would be of signiﬁcance.
38% (27/71) surgeons believed that using a tissue-
engineered ligament would give recovering patients reduced
pain or recurring injuries, with 35% (25/71) of surgeons
being unsure whether this was true. 27% (19/71) surgeons
felt that a tissue-engineered ACL would not give these added
beneﬁts.
When surgeons were asked whether they would consider
using a tissue-engineered construct that costs more than
their current procedure (for instance, up to twice the
amount) but signiﬁcantly improved the patients satisfaction
(resolution of instability/mobility/strength) 63% (45/71)
statedyes,10% (7/71) saidno, and27% (19/71) wereunsure.
There were a variety of comments left by the surgeons
when prompted. A recurring theme that surgeons were con-
cerned about with regards to the use of a tissue-engineered
ACL was of ﬁxation. For example, how will the new device
be ﬁxed into the bone and how successfully will it integrate?
Another recurring theme was the importance of reducing
donor site morbidity, which appeared to be very appealing to
the surgeons. Other comments included the need for initial
mechanical integrity of the construct to be immediately
load bearing. Many surgeons also felt that the engineered
ACL should come prepared with whip stitches ready for
implantation. Individual comments include the following:
“Would be very useful in revision ACL reconstruction,”
“The whole issue is stability. If the tissue is as good and
not signiﬁcantly more expensive I would use it,” “The key
will be getting the graft to incorporate and pick up a
blood supply. The graft will not have a nerve supply and
postoperative rehab will be unchanged as I see it while
patients restore proprioception. Engineered grafts may be
of use in revision reconstructions and in multiligament
knee injuries where autograft harvesting results in signiﬁcant
donor site morbidity and takes time.”
4. Discussion
Tissue engineering has been of increasing interest as a new
and emerging therapeutic strategy. These techniques have
been applied clinically with varying success for skin and
cartilage. Researchers are beginning to investigate new ap-
proaches to engineer replacements for the ACL [13, 14]. It
is important to include a dialogue with the end users of these
products during their development to ensure the correct
criteria are being addressed.
As such, this survey was targeted at surgeons who
performed ACL reconstruction to gain their views on how
satisﬁed they are with the current methods for ACL recon-
struction, whether there is a need for an alternative method,6 Stem Cells International
and how they would feel about using a tissue-engineered
ACL if it were an option. As with most surveys, there were
two potential sources for bias. The ﬁrst was an incomplete
sampling frame because not all specialist surgeons in the
UK could be contacted (unavailable/invalid addresses), and
the second was represented by nonresponders. However, the
data obtained are the ﬁrst, to our knowledge, to give an
indication of current clinical opinion of the potential of
tissue engineering for the ACL. This feedback is essential
to tissue engineering scientists to ensure that the correct
product goal posts are set with respect to functionality
and culture growth rate in vitro. An assessment of the
potential use of this new and emerging strategy from the
perspective of the end users of a tissue-engineered product
is important to be incorporated from the early stages of
product development.
Our data demonstrated that most of the participants had
performed surgery for more than 10 years, performing from
1 to 15 reconstructions per month, and therefore regarded as
experienced, making their opinions valuable to us. Generally
the results implied that patellar tendon and hamstring grafts
were very successful for all age groups (including athletes,)
regarding their return to physical activities with no recurring
injuries, whereas quadriceps grafts were very successful in
patients aged <56 years, with a very high percentage rating
them as “unsuccessful” compared to the patellar tendon
or hamstring. The patellar tendon is known to be a very
stiﬀ, strong tissue, if not stiﬀer than the ACL, and is also
associated with a short healing period [15], making it suit-
able choice for reconstructions, as conﬁrmed by the high
success rate indicated by the responses. Currently, the most
commonly used grafts are patellar tendon and hamstring,
but the quadriceps tendon is also becoming a popular graft,
producing fewer donor site problems than harvesting of
the patellar tendon, with excellent mechanical characteristics
[15]. From the data obtained, the percentage of respondents
who found a quadriceps graft to be very successful was much
lower than for patellar tendon and hamstring, with a rela-
tively large proportion suggesting that it was unsuccessful.
Although the current surgical procedures are successful
in a high proportion of patients, surgeons would consider
using alternative methods if they were an improvement over
existing techniques. A high proportion would be prepared
to use a tissue-engineered ACL if it were shown to have
biological and mechanical success (in vivo and in vitro)a n d
signiﬁcantly improved patients’ satisfaction, but there were
some concerns about its successful integration into bone.
It was also recognised that there would be a reduction in
scarring when tissue harvesting was not required (no donor
site), which would be another advantage to the patient. In
particular, it may be worthwhile from a tissue engineer point
of view to develop tissue-engineered ACL constructs for the
olderpatient(56yearsplus),assurgeonshavelessconﬁdence
in ACL reconstruction in this age group [16].
If the procedure time could be reduced using a tissue-
engineered ACL, it could be of beneﬁt to both patient and
the NHS, reducing anaesthetic time and surgery costs, where
a 10–30min reduction would be needed to consider it an
improvement over existing methods. Currently, the surgeons
feel that tissue engineering an ACL will not signiﬁcantly
reduce recovery time. As such, it is important for scientists
to design appropriate experiments to eﬀectively demonstrate
thattheproductsbeingdevelopedreducerecoverytime.This
should be translated into the appropriate animal model—
for example, a reduction of an 18-month recovery time by
3 months (96% of surgeons stated that 12 weeks reduction in
recovery time would be signiﬁcant to them) would produce
a 20% recovery time reduction. If a mouse ligament model
was to normally take 10 weeks to fully recover, the tissue-
engineered counterpart should demonstrate full recovery by
at least 8 weeks. Scarring did not appear to be an issue for the
surgeons.
Surgery time to reconstruct the ACL was typically stated
to last between 60 and 90 minutes. A signiﬁcant reduction of
thissurgerytimetothesurgeonswouldbe20minutes.Again,
this translates to an approximate reduction of surgery time
of 25%. These convincing statistics need to be incorporated
and considered into the preclinical animal models used by
tissue engineers when testing their products. The need for
ways to reduce surgery time was highlighted further when
the respondents were also asked for their comments which
included comments such the need for preprepared whip
stitches and easy insertion techniques.
One important factor to consider is how long the in vitro
culture can be in order to obtain the functional ligament.
This survey identiﬁes a clinical need for a stable, usable
construct by 4–6 weeks. Approximately two-thirds of the
surgeons surveyed were concerned about the method of
integration of the tissue-engineered ACL into the host bone.
Thesefactorsshouldbefullyconsideredwhendesigningsuch
a construct, and eﬀorts to demonstrate this eﬃcacy should
be included. Cost was not as much as a concern to the
clinicians than the actual performance of the replacement
ACL. The stability and potential reduction of full recovery
time of the replacement ACL was far more important than
the initial expense of the tissue engineered ACL. Recent
reviews indicate the need for improving ligament repair
[17, 18] as such, this current study indicates that clinicians
may be open to improving current methods using tissue-
engineering strategies.
5. Conclusions
The majority of British surgeons were familiar with tissue
engineering as a concept and are very open to its potential
use. Current treatments for patients over 56 years of age
have a greater need for improvement than for younger
patients. Greater patient awareness is needed with regards
to tissue engineering as a potential therapy for an increase
in potential acceptance of new strategies by these end users.
Surgeons clearly detailed a need to have a fully load-bearing
construct for implantation. Therefore, it is important for
tissue engineers to ensure that they have reliable mechanical
integrity data of their developing constructs. Currently,
surgeons are not convinced that tissue-engineered ligaments
could shorten the recovery time of the ACL in comparison
to the current methods used. Again, it is important that the
data gathered by the tissue engineer researchers eﬀectivelyStem Cells International 7
demonstrate this potential. Improvements to currently used
proceduresneedtoreducesurgerytimebyatleast20minutes
and reduce the patient time to full recovery by a minimum
of 12 weeks before surgeons feel that there is a beneﬁt.
If these criteria are met, it was not deemed as a problem
if the operation costs increased up to double the current
costs. Lastly, there is a need to have these tissue-engineered
constructs ready for use after a minimum of 4–6 weeks
in vitro culture. Any potential longer in vitro culture time
becomes unattractive for the surgeons.
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